

Supplementary Table S1 Search strategy

Concept	MeSH + synonyms
Insular glioma	Insular cortex, Insula, Island cortex, Island of Reil, Lobe of Reil, Insula of the brain, Insular lobe, Central operculum, Brain, Cerebral cortex, Limbic system, Operculum, Astrocytoma, Ependymoma, Glioma, Glioblastoma, Glioblastoma multiforme, Medulloblastoma, Oligodendroglioma, Brain cancer, Brain tumor, Glial cell tumor, Glial neoplasm, Glioma of the central nervous system, Neuroepithelial tumor, Brain tumors, Central nervous system neoplasms, Neurooncology, Oncology
Surgical approaches	Transcortical, Transopercular, Transsylvian sulcus, Lateral sulcus, Sylvian fissure, Fissure of Sylvius, Lateral Sylvian sulcus, Lateral Sylvian fissure, Brain, Cerebral cortex
Outcomes	Gross total resection, subtotal resection, partial resection, near total resection, extent of resection, postoperative, complications, deficits, mortality

Supplementary Table S2 National Heart, Lung, and Blood Institute quality assessment

Study	1	2	3	4	5	6	7	8	9	10	11	12	13	14	Rating
Duffau et al, 2000 ³³	Y	Y	Y	Y	Y	Y	Y	N	Y	NA	NA	NA	NA	NA	Fair
Lang et al, 2001 ²⁶	Y	Y	N	Y	Y	Y	Y	N	Y	NA	NA	NA	NA	NA	Fair
Simon et al, 2009 ²³	Y	Y	Y	Y	Y	Y	Y	Y	Y	NA	NA	NA	NA	NA	Fair
Duffau, 2009 ³⁴	Y	Y	Y	Y	Y	Y	Y	N	Y	-	-	-	-	-	Good
Sanai et al, 2010 ¹⁷	Y	Y	Y	Y	CD	Y	Y	Y	Y	NA	Y	NR	NA	N	Fair
Eseonu et al, 2015 ³⁵	Y	Y	Y	Y	N	Y	Y	Y	Y	NA	Y	NA	NR	Y	Fair
Hervey-Jumper et al, 2016 ³⁶	Y	Y	Y	Y	Y	Y	Y	N	Y	NA	Y	NA	NA	NA	Fair
Przybylowski et al, 2019 ⁷	Y	Y	Y	Y	Y	CD	Y	NA	Y	NA	Y	N	CD	Y	Good
Mandonnet, 2019 ³⁷	Y	Y	Y	Y	Y	Y	N	N	Y	-	-	-	-	-	Fair
Hameed et al, 2019 ¹⁹	Y	Y	Y	Y	N	Y	Y	N	Y	Y	Y	NA	N	NA	Good
Li et al, 2020 ⁹	Y	Y	Y	Y	N	Y	Y	NA	Y	NA	N	NA	NA	NA	Fair
Singh et al, 2020 ³⁸	Y	Y	Y	Y	Y	CD	Y	N	Y	NA	Y	NA	NA	NA	Fair
Panigrahi et al, 2021 ³⁹	Y	Y	Y	N	N	CD	Y	CD	Y	Y	Y	N	Y	Y	Fair
Rossi et al, 2021 ²⁰	Y	Y	Y	Y	N	Y	Y	N	Y	NA	Y	N	CD	NA	Good
Pallud et al, 2021 ⁴⁰	Y	Y	Y	CD	N	Y	Y	N	Y	Y	Y	N	Y	Y	Good
Pitshkelauri et al, 2021 ¹⁴	Y	Y	Y	Y	Y	Y	Y	Y	Y	-	-	-	-	-	Good

Abbreviation: NA, not applicable.

Risk of bias assessed using the U.S. National Institutes of Health (NIH) National Heart, Lung, and Blood Institute (NHLBI) Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies.

Question 1: Was the research question or objective in this paper clearly stated?

Question 2: Was the study population clearly specified and defined?

Question 3: Was the participation rate of eligible persons at least 50%?

Question 4: Were all the subjects selected or recruited from the same or similar populations (including the same time period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants?

Question 5: Was a sample size justification, power description, or variance and effect estimates provided?

Question 6: For the analyses in this paper, were the exposure(s) of interest measured prior to the outcome(s) being measured?

Question 7: Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed?

Question 8: For exposures that can vary in amount or level, did the study examine different levels of the exposure as related to the outcome (e.g., categories of exposure, or exposure measured as continuous variable)?

Question 9: Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?

Question 10: Was the exposure(s) assessed more than once over time?

Question 11: Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants?

Question 12: Were the outcome assessors blinded to the exposure status of participants?

Question 13: Was loss to follow-up after baseline 20% or less?

Question 14: Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)?

Risk of bias for case series assessed using NHLBI

1. Was the study question or objective clearly stated?
2. Was the study population clearly and fully described, including a case definition?
3. Were the cases consecutive?
4. Were the subjects comparable?
5. Was the intervention clearly described?
6. Were the outcome measures clearly defined, valid, reliable, and implemented consistently across all study participants?
7. Was the length of follow-up adequate?
8. Were the statistical methods well-described?
9. Were the results well-described?

Supplementary Table S3 Preoperative deficit details of included studies

Study	Preoperative neurological deficits							
	Motor deficits	Sensory deficits	Speech deficits	Seizure	Raised ICP	Headache	Dizziness	Other
Duffau et al, 2000 ³³	02	02	02	12	NR	NR	NR	NR
Lang et al, 2001 ²⁶	07	NR	04	14	NR	NR	NR	NR
Simon et al, 2009 ²³	NR	NR	NR	83	NR	NR	NR	NR
Duffau, 2009 ³⁴	1	NR	5	50	1	NR	NR	NR
Hervey-Jumper et al, 2016 ³⁶	03	NR	1	88	NR	9	NR	NR
Przybylowski et al, 2019 ⁷	NR	NR	NR	61	NR	NR	NR	NR
Li et al, 2020 ⁹	27	–	8	144	–	74	52	NR
Panigrahi et al, 2021 ³⁹	7	1	7	33	11	NR	NR	NR
Rossi et al, 2021 ²⁰	11	3	16	70 (73.7%)	NR	NR	NR	NR
Singh et al, 2020 ³⁸	NR	9	NR	14	NR	17	NR	NR
Sanai et al, 2010 ¹⁷	NR	13	5	75	NR	7	NR	NR
Pallud et al, 2021 ⁴⁰	NR	29	NR	111	NR	20	NR	NR
Mandonnet, 2019 ³⁷	NR	NR	NR	11	NR	1	NR	NR
Pitskhelauri et al, 2021 ¹⁴	NR	NR	NR	58	1	NR	NR	NR
Eseonu et al, 2017 ³⁵	17	5	12	26	NR	14	NR	NR
Hameed et al, 2019 ¹⁹	NR	NR	NR	104	NR	NR	NR	NR

Abbreviation: NR, not reported.

Supplementary Table S4 Pre- and postoperative Karnofsky Performance Scale scores

Study	Preoperative KPS scores	Postoperative KPS scores	
Duffau et al, 2000 ³³	NR	NR	
Lang et al, 2001 ²⁶	NR	NR	
Simon et al, 2009 ²³	Mean KPS: 85 ± 14 82% (80–100) 13% (60–70)	Mean KPS score at 3-month follow-up: 79 ± 8 68% (80–100) 25% (60–70) 10 cases had KPS scores <60	
Duffau, 2009 ³⁴	KPS scores value 70: 1 80: 5 90: 22 100: 23	KPS scores value 70: 2 8: 2 90: 24 100: 23	
Hervey-Jumper et al, 2016 ³⁶	NR	NR	
Przybylowski et al, 2019 ⁷	NR	NR	
Li et al, 2020 ⁹	NR	NR	
Panigrahi et al, 2021 ³⁹	KPS scores >70 Transopercular: 28 (87%) Transsylvian: 36 (92.1%)	NR	
Rossi et al, 2021 ²⁰	NR	NR	
Singh et al, 2020 ³⁸	KPS score >80: 12 KPS score <80: 15	Median KPS score: 65 (range 0–100)	
Sanai et al, 2010 ¹⁷	KPS at diagnosis Median: 84 (range 18–75)	NR	
Pallud et al, 2021 ⁴⁰	Whole series (<i>n</i> = 149) Mean: 90.6 ± 9.9 ≥70: 145, <70: 4 Awake resection (<i>n</i> = 61) Mean: 93.9 ± 9.4 ≥70: 60, <70: 1 Asleep resection (<i>n</i> = 50) Mean: 87.0 ± 9.3 ≥70: 48, <70: 2 Biopsy subgroup (<i>n</i> = 38) Mean: 90.0 ± 10.1 ≥70: 37, <70: 1	Early postoperative KPS score Awake resection (<i>n</i> = 61) Mean: 80.2 ± 10.9 ≥70: 57, <70: 4 Asleep resection (<i>n</i> = 50) Mean 76.1 ± 13.9 ≥70: 33, <70: 5 Biopsy subgroup (<i>n</i> = 38) Mean 84.8 ± 12.9 ≥70: 27, <70: 2	3-month postoperative KPS score Awake resection (<i>n</i> = 61) Mean 92.7 ± 10.7 ≥70: 55, <70: 6 Asleep resection (<i>n</i> = 50) Mean 82.4 ± 12.5 ≥70: 41, <70: 5 Biopsy subgroup (<i>n</i> = 38) Mean 80.0 ± 21.4 ≥70: 30, <70: 5
Mandonnet, 2019 ³⁷	NR	NR	
Pitshkelaury et al, 2021 ¹⁴	Median 88 (range 60–100)	Median 82.8 (range 40–100)	
Eseonu et al, 2017 ³⁵	Median 80 (range 50–100)	Median 80 (range 50–100)	
Hameed et al, 2019 ¹⁹	KPS score ≥90 in 90.80% of patients	NR	

Abbreviations: KPS, Karnofsky Performance Scale; NR, not reported.